Control of cell proliferation and apoptosis by mob as tumor suppressor, mats.
By Z. Lai, Xiaomu Wei, Takeshi Shimizu, Edward Ramos, M. Rohrbaugh, N. Nikolaidis, L. Ho, Y. Li. Cell, 2005
614 citations recorded by the source corpus.
Subfields: Cell Biology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/aa50d9775d57dd03e5f9f877ade2c1bbd1517926
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Molecular Biology
Citations in the corpus
- TEAD mediates YAP-dependent gene induction and growth control. (2008, background): “Recent genetic studies in Drosophila have identified a novel tumor suppressor pathway, the Hippo pathway (Harvey et al. 2003; Wu et al. 2003; Lai et al. 2005; Edgar 2006; Hariharan and Bilder 2006; Harvey and Tapon 2007).”
- Hippo signaling in organ size control. (2007, background): “For example, mice lacking a wts homolog develop soft-tissue sarcomas and ovarian tumors (St John et al. 1999), and the human orthologs of sav and mats are mutated in several cancer cell lines (Tapon et al. 2002; Lai et al. 2005).”
- The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal (2011, neutral): “Biochemical studies revealed that Hpo directly interacts with Sav to phosphorylate and activate the complex formed by Wts and another core Hippo pathway protein, Mat”
- The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. (2008, background): “Wts, facilitated by the Mob family protein Mats (Lai et al., 2005), phosphorylates the transcriptional coacti-”
- Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. (2011, background): “…mutation of the Hippo pathway genes or transgenic expression of Yki, the YAP homolog, results in enlarged organ size (Kango-Singh et al. 2002; Tapon et al. 2002; Harvey et al. 2003; Jia et al. 2003; Pantalacci et al. 2003; Udan et al. 2003; Wu et al. 2003; Huang et al. 2005; Lai et al. 2005).”
- Mechanisms of Hippo pathway regulation (2016, neutral): “GPCRs are the largest family of the plasma membrane receptors and mediate the actions of hundreds of extracellular molecules (Lap- pano and Maggiolini 2011).”
- The Hippo Signaling Pathway in Development and Disease (2019, background): “The Transcriptional Machinery of the Hippo Pathway The Hippo kinase cascade converges on its nuclear effector Yki/YAP/TAZ to regulate gene expression programs.”
- TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway (2008, background): “also been implicated in human cancer (14, 28, 29, 31).”
- The Hippo signaling pathway in stem cell biology and cancer (2014, neutral): “Hpo complexes with the scaffolding protein Sav (Salvador) to phosphorylate and activate Wts, which then forms a complex with its regulatory protein Mats (Mob as tumor suppressor) [8 – 10].”
- The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals (2010, background): “At the core of the Hippo signaling pathway is a kinase cascade composed of four tumor suppressor proteins, including the Ste20-like kinase Hippo (Hpo) (Wu et al., 2003; Udan et al., 2003; Harvey et al., 2003; Pantalacci et al., 2003; Jia et al., 2003) and its regulatory protein Salvador (Sav) (Tapon”
- The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. (2008, background): “Wts acts in a complex with Mats to restrict cell growth and proliferation and promote cell death by regulating the transcription of Hpo pathway target genes including cyclin E (cycE), diap1, and bantam (Harvey et al., 2003; Jia et al., 2003; Lai et al., 2005; Pantalacci et al., 2003; Thompson and Co”